The Lancet calls on drugs industry to fund more "personalised" cancer trials
This article was originally published in Scrip
Executive Summary
In an editorial entitled, "Cancer: the revolution has begun," The Lancet has called on the pharmaceutical industry to more often fund clinical trials that stratify cancer patients by known or potential biomarkers. And while many recently completed and ongoing industry-sponsored Phase III trials have not in fact been stratified, leading cancer drug developers assert that "personalised medicine" is in fact their focus.